M&T Bank’s Accelerate Diagnostics AXDX Stock Holding History

M&T Bank’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,337	Closed	-$142K	–	1700
2020 Q3	$142K	Buy	1,337 +296	+28%	+$41.1K	﹤0.01%	1465
2020 Q2	$158K	Hold	1,041	–	–	﹤0.01%	1411
2020 Q1	$87K	Sell	1,041 -6	-0.6%	-$844	﹤0.01%	1433
2019 Q4	$177K	Buy	+1,047	New	+$173K	﹤0.01%	1281
2019 Q3	–	Sell	-903	Closed	-$206K	–	1612
2019 Q2	$206K	Buy	+903	New	+$177K	﹤0.01%	1409

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

M&T Bank's AXDX Position: Q4 2020 in Review

M&T Bank sold out of Accelerate Diagnostics (AXDX) in Q4 2020, closing a stake of 1,337 shares — an estimated $142K sold.

M&T Bank first reported a position in AXDX in Q2 2019 and held it in 5 quarters. The position peaked at $206K in Q2 2019. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

M&T Bank reported no remaining Accelerate Diagnostics position as of Q4 2020 after selling out during the quarter.
M&T Bank sold 1,337 Accelerate Diagnostics shares in Q4 2020, an estimated $142K.
M&T Bank first reported a position in Accelerate Diagnostics in Q2 2019 and held it in 5 quarters.
M&T Bank's Accelerate Diagnostics position peaked at $206K in Q2 2019.
115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on M&T Bank's 13F filing for Q4 2020, filed 12 Feb 2021.